spectrometer as KBr pellets. Elemental analysis was preformed
using a Perkin Elmer Autosystem XL Analyzer. Melting points
were measured using a COMPLAB melting-point apparatus.
Reactions were monitored by thin-layer chromatography (TLC)
carried out on 0.25 mm silica gel plates visualized with UV light.
General procedure for synthesis of compounds 3(a–x)
Isatin (1 mmol.) and isatoic anhydride (1 mmol.) were combined
with 10 ml distilled water in a 50 ml roundbottomed flask
equipped with a stir bar. b-cyclodextrin (20 mol%) was added.
Reaction was allowed to stir at room temperature for the
appropriate amount of time. After completion of reaction, the
reaction mixture was extracted with ethyl acetate. Organic layer
was dried over Na2SO4 and concentrated in vacuo to give crude
product which was further purified by column chromatography.
Indolo[2,1-b]quinazoline-6,12-dione (3a)
◦
Yellow solid. mp > 250 C. Found C, 72.52, H, 3.19, N, 11.22
C15H8N2O2 requires C, 72.58, H, 3.25, N, 11.28%. nmax(KBr):
3062, 1721, 1645, 1435, 1256, 804, 747 cm-1. 1H NMR (300 MHZ,
CDCl3) d = 8.61 (d, 1H, J = 3.4 Hz), 8.44 (d, 1H, J = 5.4 Hz),
8.06 (d, 1H, J = 8.1 Hz), 7.94–7.80 (m, 3H), 7.69 (t, 1H, J =
7.08 Hz), 7.28 (t, 1H, J = 7.1 Hz). 13C NMR (75 MHZ, CDCl3)
d = 117.5, 120.6, 125.4, 126.3, 127.1, 129.7, 130.0, 133.2, 134.6,
145.3, 146.6, 160.4, 183.8.∑ ESIMS: m/z 249 (M+H).
2-Bromoindolo[2,1-b]quinazoline-6,12-dione(3b)
Light yellow solid; mp > 250 ◦C. Found C, 54.98, H, 2.13
N, 8.48 C15H7BrN2O2 requires C, 55.07; H, 2.16; N, 8.56%.
n
max(KBr):3124, 1724, 1647, 1440, 1255, 812, 746 cm-1. 1H NMR
(300 MHZ, CDCl3) d = 8.24 (s, 1H), 8.10–8.02 (m, 2H), 7.98–7.82
(m, 2H), 7.63 (t, 1H, J = 7.2 Hz), 7.38 (t, 1H, J = 6.3 Hz). 13C
NMR (75 MHZ, CDCl3) d = 117.8, 120.7, 123.0, 123.5, 125.7,
129.4, 129.9, 132.3, 134.8, 136.2, 146.4, 160.8, 182.5. ESIMS:
m/z 326 (M+H).
Fig. 3 1H NMR spectra of A) b-CD B) b-CD complex C) freeze-dried
reaction mixture after 2 h.
References
1 (a) C. M. Martı´ınez-Viturro and D. Domı´ınguez, Tetrahedron Lett.,
2007, 48, 1023–1026; (b) K. Dzierzbicka, P. Trzonkowski, P. L.
Sewerynek and A. Mysliwski, J. Med. Chem., 2003, 46, 978–986.
2 S.-T. Yu, T.-M. Chen, S.-Y. Teng and Y.-H. Chen, Biochem. Biophys.
Res. Commun., 2007, 358, 79–84.
3 T. Yasutaka, S. Takao, W. Nobuhisa, A. Hideyuki, S. Shigeru and S.
Isao, J. Med. Chem., 1994, 37, 2106–2111.
4 L. A. Mitscher and W. Baker, Med. Res. Rev., 1998, 18, 363–374.
5 A. K. Bhattacharjee, D. J. Skanchy, B. Jennings, T. H. Hudson, J. J.
Brendle and K. A. Werbovetz, Bioorg. Med. Chem., 2002, 10, 1979–
1989.
6 W. R. Baker and L. A. Mitscher, Indolo{2,1-biquinazoline-6.12-
dione Antibacterial Compounds and Methods of Use Thereof,
U.S. Patent, 5, 441, 955, 1995.
Fig. 4 Catalyst (b-cyclodextrin) recyclability data.
Experimental
7 S. B. Phadtare and G. S. Shankarling, Green Chem., 2010, 12, 458–
462.
All the reactions were carried out at room temperature that is
28–32 ◦C. Unless otherwise specified, all the reagents were pur-
chased from Sigma-Aldrich Chemical Co, Lancaster and were
used directly without further any purification. NMR spectra
were obtained using the Brucker DRX 300 MHz spectrometer.
Chemical shifts (d) are given in ppm relative to TMS, coupling
constants (J) in Hz. IR spectra were taken on VARIAN FT-IR
8 S. C. Harvey, in Goodman and Gilman’s The Therapeutic Basis of
Therapeutics; A. G. Gilman, L. S. Goodman, ed. 6th ed.; MacMillan,
New York, 1980, p 367.
9 (a) E. S. Lee, J. G. Park and Y. Jahng, Tetrahedron Lett., 2003, 44,
1883–1886; (b) B. Batanero and F. Barba, Tetrahedron Lett., 2006,
47, 8201–8203.
10 (a) K. M. Amin, M. M. Kamel, M. M. Anwar, M. Khedr and Y. M.
Syamb, Eur. J. Org. Chem., 2010, 45, 2117–2131; (b) K. C. Jahng,
This journal is
The Royal Society of Chemistry 2011
Green Chem., 2011, 13, 51–54 | 53
©